Cargando…

Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor–Positive, ERBB2-Positive, Node-Negative Breast Cancer

This cohort study examines the association of survival with adjuvant chemoendocrine therapy for hormone receptor–positive, ERBB2-positive, node-negative breast cancer.

Detalles Bibliográficos
Autores principales:	Ma, Sung Jun, Oladeru, Oluwadamilola T., Singh, Anurag K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146098/ https://www.ncbi.nlm.nih.gov/pubmed/32271387 http://dx.doi.org/10.1001/jamanetworkopen.2020.2507

Ejemplares similares

Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2020)

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
por: Oladeru, Oluwadamilola T., et al.
Publicado: (2020)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
por: Ma, Sung Jun, et al.
Publicado: (2023)

Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor–Positive Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2023)

Effects of Chemoendocrine Therapy on the Coagulation‐Fibrinolytic Systems in Patients with Advanced Breast Cancer
Publicado: (1993)

Evaluation of Preoperative Chemotherapy or Radiation and Overall Survival in Patients With Nonmetastatic, Resectable Retroperitoneal Sarcoma
por: Ma, Sung Jun, et al.
Publicado: (2020)

Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer
por: Ma, Sung Jun, et al.
Publicado: (2019)

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Bao, Kelvin K. H., et al.
Publicado: (2021)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2022)

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer
por: Lovejoy, Leann A., et al.
Publicado: (2023)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

A robust prognostic signature for hormone-positive node-negative breast cancer
por: Griffith, Obi L, et al.
Publicado: (2013)

CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer
por: Kuo, Sung-Hsin, et al.
Publicado: (2013)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Li, Xuanyi, et al.
Publicado: (2022)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer
por: Brufsky, Adam M.
Publicado: (2014)

Tumor Characteristics Associated with Lymph Node Metastasis and Prognosis in Patients with ERBB2-Positive Gastric Cancer
por: Xu, Ran, et al.
Publicado: (2022)

Adjuvant chemotherapy, not radiotherapy, prolongs survival for node-negative non–small cell lung cancer with positive surgical margins
por: Ashrafi, Arman, et al.
Publicado: (2023)

Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
por: Chen, Jonathan, et al.
Publicado: (2018)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma
por: Sugano, Teppei, et al.
Publicado: (2020)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

The Role of the 21-Gene Recurrence Score(®) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
por: Yordanova, Mariya, et al.
Publicado: (2022)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

A Paradigm Shift in Radiation Oncology Training
por: Perni, Subha, et al.
Publicado: (2020)

Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
por: Murata, Takeshi, et al.
Publicado: (2023)

Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients
por: Taubenhansl, Clara, et al.
Publicado: (2019)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

Prognostic significance of c-erbB-2 expression in node negative breast cancer.
por: Bianchi, S., et al.
Publicado: (1993)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Increased number of negative lymph nodes is associated with improved survival outcome in node positive gastric cancer following radical gastrectomy
por: Shi, Rong-liang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1v4ug8427pu1j1tla42sea2vk1